Zobrazeno 1 - 10
of 1 278
pro vyhledávání: ''
Autor:
Ryusaku Matsumoto, Masaaki Yamamoto, Genzo Iguchi, Shin Urai, Hidenori Fukuoka, Wataru Ogawa, Kentaro Suda, Hiroki Shichi, Keitaro Kanie, Yutaka Takahashi, Hironori Bando, Yasunori Fujita
Publikováno v:
Cancer Immunology, Immunotherapy
Background Immune checkpoint inhibitors (ICIs) as a cancer immunotherapy have emerged as a treatment for multiple advanced cancer types. Because of enhanced immune responses, immune-related adverse events (irAEs), including endocrinopathies such as h
Autor:
Shigeyuki Shichino, Hiromichi Nakajima, Yoshiaki Nakamura, Tetsuya Nakatsura, Satoshi Ueha, Manami Shimomura, Hiroyasu Aoki, Akihiro Sato, Kouji Matsushima, Takayuki Yoshino
Publikováno v:
Cancer Science
With the widespread use of programmed death receptor‐1 (PD‐1) blockade therapy, sensitive and specific predictive biomarkers that guide patient selection are urgently needed. T‐cell receptor (TCR) repertoire, which reflects antitumor T‐cell r
Autor:
Laurence Kraus-Berthier, Lucie Laplane, Véronique Saada, Céline Berthon, Maria E. Figueroa, Bouchra Badaoui, Margaux Sevin, Franck Debeurme, Eric Padron, Thorsten Braun, Qin Yang, Nathalie Droin, Raphael Itzykson, Guido Kroemer, Dorothée Selimoglu-Buet, Eric Solary, Oliver Kepp, Margot Morabito, Alix Derreal, Hannah Newman, Sylvain Thepot, Gabriel Etienne, Miguel Torres-Martin, Sébastien Banquet, Severine Badel, Orianne Wagner-Ballon, Pierre Fenaux
Publikováno v:
Blood
Blood, American Society of Hematology, 2021, 137 (24), pp.3390-3402. ⟨10.1182/blood.2020008729⟩
Blood, American Society of Hematology, 2021, 137 (24), pp.3390-3402. ⟨10.1182/blood.2020008729⟩
Mouse models of chronic myeloid malignancies suggest that targeting mature cells of the malignant clone disrupts feedback loops that promote disease expansion. Here, we show that in chronic myelomonocytic leukemia (CMML), monocytes that accumulate in
Publikováno v:
Journal of Immunotherapy. 44:234-238
Immunotherapy has revolutionized the treatment of advanced cutaneous squamous cell carcinoma. However, the role of immune checkpoint inhibitors for the treatment of Marjolin ulcer (MU), a rare cutaneous malignancy that arises from previously traumati
Autor:
Jan Budczies, Cornelius F. Waller, Amanda Tufman, Martina Kirchner, Torsten Goldmann, Albrecht Stenzinger, Peter Schirmacher, Petros Christopoulos, Michael Meister, Mark Kriegsmann, Michael Thomas, Martin Reck, Solange Peters, Klaus Kluck, Hauke Winter, Julia Glade, Daniel Kazdal, Stefan Fröhling, Michael Allgäuer, Thomas Muley, Felix J.F. Herth, CP Heußel, Martin Wermke
Publikováno v:
Cancer Immunology, Immunotherapy
Introduction The advent of immune checkpoint blockade (ICB) has led to significantly improved disease outcome in lung adenocarcinoma (ADC), but response of ALK/EGFR-positive tumors to immune therapy is limited. The underlying immune biology is incomp
Autor:
Eiji Takeuchi, Hisanori Machida, Naoki Kadota, Tsutomu Shinohara, Keishi Naruse, Yoshio Okano, Nobuo Hatakeyama, Yoshihiro Kondou, Katsuhiro Atagi
Publikováno v:
Cancer Immunology, Immunotherapy
Objective Tumor-related eosinophilia may have extended survival benefits for some cancer patients. However, there has been no report on the prognosis difference between eosinophilic pleural effusion (EPE) and non-EPE in lung cancer patients. Our stud
Autor:
Salvatore Siena, Emilia Maria Cristina Mazza, Giulia Della Chiara, Chiara Godano, Nicola Zucchini, Valeria Ranzani, Stefania Oliveto, Paola Gruarin, Jens Geginat, Roberto Bosotti, Claudia D'Oria, Elena Carelli, Pierluigi Novellis, Saveria Mazzara, Ylenia Silvestri, Marco Passaro, Alessio Amatu, Marco Alloisio, Antonio Lanzavecchia, Stefano Biffo, Giorgia Alvisi, Federica Gervasoni, Maria Lucia Sarnicola, N. Mariani, Alberto Bardelli, Ramona Bason, Jolanda Brummelman, Mariangela Lorenzo, Giulia Veronesi, Emanuela Bonoldi, Massimiliano Pagani, Daniele Prati, Enrico Opocher, Lorenzo Drufuca, Martina Martinovic, Andrea Sartore-Bianchi, Sergio Abrignani, Alessandro Giani, Marco De Simone, Enrico Lugli, Chiara Cordiglieri, Serena Curti, Grazisa Rossetti, Valeria Bevilacqua, Andrea Pisani Ceretti, Raoul J. P. Bonnal
Publikováno v:
Nature Immunology, 22, 735-745
Nature Immunology, 22, 6, pp. 735-745
Nature Immunology, 22, 6, pp. 735-745
Regulatory T (Treg) cells are a barrier for tumor immunity and a target for immunotherapy. Using single-cell transcriptomics, we found that CD4+ T cells infiltrating primary and metastatic colorectal cancer and non-small-cell lung cancer are highly e
Publikováno v:
Cancer Immunology, Immunotherapy. 71:25-38
Tumor-infiltrating CD8 cells and expression of programmed cell death ligand 1 (PD-L1) are immune checkpoint markers in patients with hepatocellular carcinoma (HCC). We aimed to determine the ability of preoperative gadoxetic acid-enhanced magnetic re
Autor:
Olivier Tredan, Romaine Mayet, Magali Morelle, Benoit You, François Parant, Marine Villard, Isabelle Ray-Coquard, Thomas Bachelot, Sébastien Viel, David Pérol, Emily Charrier, Yamila Rocca, Gwenaële Garin, Antoine Marçais, Laurie Besson, Pierre Heudel, Thierry Walzer, Benoîte Méry
Publikováno v:
Journal of Immunology
Journal of Immunology, Publisher : Baltimore : Williams & Wilkins, c1950-. Latest Publisher : Bethesda, MD : American Association of Immunologists, 2021, 206 (10), pp.2265-2270. ⟨10.4049/jimmunol.2001215⟩
Journal of Immunology, Publisher : Baltimore : Williams & Wilkins, c1950-. Latest Publisher : Bethesda, MD : American Association of Immunologists, 2021, 206 (10), pp.2265-2270. ⟨10.4049/jimmunol.2001215⟩
NK cells are cytotoxic lymphocytes displaying strong antimetastatic activity. Mouse models and in vitro studies suggest a prominent role of the mechanistic target of rapamycin (mTOR) kinase in the control of NK cell homeostasis and antitumor function
Autor:
Jürgen C. Becker, Stephan Grabbe, Ulrike Leiter, Henner Stege, Claudia Pföhler, Peter Mohr, Jessica C. Hassel, Carmen Loquai, S. Schultheis, Felix Kiecker, S. Ugurel, Maximilian Haist, Patrick Terheyden, Markus Meissner, Maria Isabel Fleischer, J. Kleeman, A. Thiem
Publikováno v:
Cancer Immunology, Immunotherapy
Background Immune checkpoint inhibitors (ICI) have led to a prolongation of progression-free and overall survival in patients with metastatic Merkel cell carcinoma (MCC). However, immune-mediated adverse events due to ICI therapy are common and often